Aclaris Therapeutics to Webcast Conference Call Discussing Fourth Quarter and Full Year 2017 Financial Results on March 12, 2...
February 28 2018 - 8:00AM
Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led
biopharmaceutical company focused on identifying, developing, and
commercializing innovative and differentiated therapies to address
significant unmet needs in medical and aesthetic dermatology, will
report financial results for the fourth quarter and year ending
December 31, 2017 on Monday, March 12, 2018, before the U.S.
financial markets open.
Management will provide an update on the Company and discuss
fourth quarter and year-end 2017 results as well as expectations
for the future via conference call on Monday, March 12, 2018,
at 8:00 AM ET. To participate on the live call, please dial
(844) 776-7782 (domestic) or (661) 378-9535 (international), and
reference conference ID 1495576 prior to the start
of the call.
A live webcast of the event can be accessed on the Events and
Presentations page on the Investors section of the Aclaris website
at http://www.aclaristx.com/events-and-webcasts. A replay of the
webcast will be archived on the Aclaris website following the
event.
About Aclaris
Therapeutics, Inc. Aclaris Therapeutics, Inc. is a
dermatologist-led biopharmaceutical company committed to
identifying, developing and commercializing innovative therapies to
address significant unmet needs in aesthetic and medical
dermatology and immunodermatology. The Company is focused on market
segments with no FDA-approved medications or where treatment
gaps exist. Aclaris is based in Wayne, Pennsylvania and
more information about the company can be found by visiting the
Aclaris website at www.aclaristx.com.
Contact:
Aclaris Contact Michael Tung, M.D. Senior Vice President /
Corporate Strategy / Investor Relations 484-329-2140
mtung@aclaristx.com
Media Contact Laura Morgan TogoRun 347-342-8496
L.Morgan@togorun.com
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Jul 2023 to Jul 2024